nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—Protein Kinase Inhibitors—Vemurafenib—melanoma	0.45	1	CiPCiCtD
Nilotinib—BRAF—Vemurafenib—melanoma	0.113	0.722	CbGbCtD
Nilotinib—EPHA2—melanoma	0.112	0.467	CbGaD
Nilotinib—PDGFRA—melanoma	0.0455	0.189	CbGaD
Nilotinib—BRAF—melanoma	0.0416	0.173	CbGaD
Nilotinib—KIT—melanoma	0.0334	0.139	CbGaD
Nilotinib—ABCG2—Vemurafenib—melanoma	0.0128	0.0818	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—melanoma	0.00848	0.0544	CbGbCtD
Nilotinib—ABCB1—melanoma	0.00769	0.032	CbGaD
Nilotinib—CYP3A4—Temozolomide—melanoma	0.00503	0.0323	CbGbCtD
Nilotinib—ABCG2—Docetaxel—melanoma	0.00438	0.0281	CbGbCtD
Nilotinib—CYP2D6—Vemurafenib—melanoma	0.00434	0.0278	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—melanoma	0.00306	0.0196	CbGbCtD
Nilotinib—CYP3A4—Vemurafenib—melanoma	0.00276	0.0177	CbGbCtD
Nilotinib—ABCB1—Docetaxel—melanoma	0.00158	0.0101	CbGbCtD
Nilotinib—MAPK8—skin epidermis—melanoma	0.000995	0.0367	CbGeAlD
Nilotinib—CA6—ear—melanoma	0.000967	0.0357	CbGeAlD
Nilotinib—CYP3A4—Docetaxel—melanoma	0.000946	0.00607	CbGbCtD
Nilotinib—CA3—ear—melanoma	0.000916	0.0338	CbGeAlD
Nilotinib—MAPK8—endothelium—melanoma	0.000722	0.0266	CbGeAlD
Nilotinib—MAPK8—blood vessel—melanoma	0.000666	0.0245	CbGeAlD
Nilotinib—TIE1—endothelium—melanoma	0.000626	0.0231	CbGeAlD
Nilotinib—TIE1—blood vessel—melanoma	0.000577	0.0213	CbGeAlD
Nilotinib—CA6—hair follicle—melanoma	0.00051	0.0188	CbGeAlD
Nilotinib—MAPK8—neck—melanoma	0.000476	0.0176	CbGeAlD
Nilotinib—Ponatinib—PDGFRA—melanoma	0.000457	0.252	CrCbGaD
Nilotinib—MAPK14—hair follicle—melanoma	0.000451	0.0166	CbGeAlD
Nilotinib—EPHB2—retina—melanoma	0.000439	0.0162	CbGeAlD
Nilotinib—EPHB4—endothelium—melanoma	0.000435	0.016	CbGeAlD
Nilotinib—EPHA8—eye—melanoma	0.000425	0.0157	CbGeAlD
Nilotinib—MAPK14—blood vessel—melanoma	0.000423	0.0156	CbGeAlD
Nilotinib—TEK—endothelium—melanoma	0.000416	0.0153	CbGeAlD
Nilotinib—KIT—skin epidermis—melanoma	0.000415	0.0153	CbGeAlD
Nilotinib—EPHB4—blood vessel—melanoma	0.000401	0.0148	CbGeAlD
Nilotinib—EPHA2—blood vessel—melanoma	0.000393	0.0145	CbGeAlD
Nilotinib—CDC42BPB—eye—melanoma	0.000392	0.0144	CbGeAlD
Nilotinib—CDC42BPB—retina—melanoma	0.000388	0.0143	CbGeAlD
Nilotinib—TEK—blood vessel—melanoma	0.000384	0.0141	CbGeAlD
Nilotinib—EPHA3—eye—melanoma	0.000371	0.0137	CbGeAlD
Nilotinib—EPHA3—retina—melanoma	0.000368	0.0136	CbGeAlD
Nilotinib—Ponatinib—KDR—melanoma	0.000355	0.196	CrCbGaD
Nilotinib—MAPK8—eye—melanoma	0.000354	0.0131	CbGeAlD
Nilotinib—MAPK8—retina—melanoma	0.000351	0.0129	CbGeAlD
Nilotinib—Ponatinib—KIT—melanoma	0.000335	0.185	CrCbGaD
Nilotinib—MAP4K1—retina—melanoma	0.000319	0.0118	CbGeAlD
Nilotinib—MAPK8—skin of body—melanoma	0.000308	0.0114	CbGeAlD
Nilotinib—MAPK14—neck—melanoma	0.000302	0.0112	CbGeAlD
Nilotinib—KIT—endothelium—melanoma	0.000301	0.0111	CbGeAlD
Nilotinib—Imatinib—PDGFRA—melanoma	0.000281	0.155	CrCbGaD
Nilotinib—KIT—blood vessel—melanoma	0.000278	0.0102	CbGeAlD
Nilotinib—PDGFRB—blood vessel—melanoma	0.000271	0.01	CbGeAlD
Nilotinib—MAP4K1—mammalian vulva—melanoma	0.000255	0.00942	CbGeAlD
Nilotinib—EPHB2—head—melanoma	0.000252	0.00928	CbGeAlD
Nilotinib—EPHA8—head—melanoma	0.000241	0.00889	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—melanoma	0.000232	0.00855	CbGeAlD
Nilotinib—MAPK11—head—melanoma	0.000224	0.00827	CbGeAlD
Nilotinib—CDC42BPB—head—melanoma	0.000222	0.0082	CbGeAlD
Nilotinib—HCK—mammalian vulva—melanoma	0.000213	0.00786	CbGeAlD
Nilotinib—EPHA3—head—melanoma	0.000211	0.00777	CbGeAlD
Nilotinib—Imatinib—KIT—melanoma	0.000206	0.114	CrCbGaD
Nilotinib—MAPK8—head—melanoma	0.000201	0.00742	CbGeAlD
Nilotinib—EPHA6—head—melanoma	0.000201	0.00742	CbGeAlD
Nilotinib—KIT—neck—melanoma	0.000199	0.00733	CbGeAlD
Nilotinib—MAPK14—skin of body—melanoma	0.000196	0.00722	CbGeAlD
Nilotinib—PDGFRB—neck—melanoma	0.000194	0.00716	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—melanoma	0.000194	0.00714	CbGeAlD
Nilotinib—LYN—head—melanoma	0.000186	0.00684	CbGeAlD
Nilotinib—BLK—lymph node—melanoma	0.000178	0.00657	CbGeAlD
Nilotinib—LCK—mammalian vulva—melanoma	0.000178	0.00656	CbGeAlD
Nilotinib—FGR—mammalian vulva—melanoma	0.000178	0.00656	CbGeAlD
Nilotinib—CA2—hair follicle—melanoma	0.000176	0.00647	CbGeAlD
Nilotinib—TIE1—head—melanoma	0.000174	0.00643	CbGeAlD
Nilotinib—CA12—eye—melanoma	0.000171	0.00629	CbGeAlD
Nilotinib—EPHB6—skin of body—melanoma	0.00017	0.00626	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—melanoma	0.000169	0.00624	CbGeAlD
Nilotinib—EPHA2—mammalian vulva—melanoma	0.000166	0.00612	CbGeAlD
Nilotinib—EPHB3—head—melanoma	0.000166	0.00612	CbGeAlD
Nilotinib—CSF1R—eye—melanoma	0.000163	0.006	CbGeAlD
Nilotinib—MAPK11—lymph node—melanoma	0.000157	0.00579	CbGeAlD
Nilotinib—CDC42BPB—lymph node—melanoma	0.000156	0.00574	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—melanoma	0.000155	0.00571	CbGeAlD
Nilotinib—HCK—head—melanoma	0.000152	0.00562	CbGeAlD
Nilotinib—EPHA3—lymph node—melanoma	0.000148	0.00544	CbGeAlD
Nilotinib—CA6—head—melanoma	0.000144	0.00533	CbGeAlD
Nilotinib—PDGFRB—eye—melanoma	0.000144	0.00532	CbGeAlD
Nilotinib—CA4—neck—melanoma	0.000142	0.00524	CbGeAlD
Nilotinib—CSF1R—skin of body—melanoma	0.000142	0.00522	CbGeAlD
Nilotinib—MAPK8—lymph node—melanoma	0.000141	0.00519	CbGeAlD
Nilotinib—EPHA4—head—melanoma	0.000139	0.00511	CbGeAlD
Nilotinib—CA3—head—melanoma	0.000137	0.00505	CbGeAlD
Nilotinib—CA1—eye—melanoma	0.000135	0.00499	CbGeAlD
Nilotinib—MAP2K5—mammalian vulva—melanoma	0.000132	0.00488	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—melanoma	0.000129	0.00476	CbGeAlD
Nilotinib—ABL1—eye—melanoma	0.000129	0.00475	CbGeAlD
Nilotinib—KIT—skin of body—melanoma	0.000129	0.00474	CbGeAlD
Nilotinib—MAP4K1—lymph node—melanoma	0.000128	0.00472	CbGeAlD
Nilotinib—MAPK14—head—melanoma	0.000128	0.00471	CbGeAlD
Nilotinib—ABL1—retina—melanoma	0.000128	0.0047	CbGeAlD
Nilotinib—FGR—head—melanoma	0.000127	0.00469	CbGeAlD
Nilotinib—PDGFRB—skin of body—melanoma	0.000126	0.00463	CbGeAlD
Nilotinib—TIE1—lymph node—melanoma	0.000122	0.0045	CbGeAlD
Nilotinib—EPHA2—head—melanoma	0.000119	0.00438	CbGeAlD
Nilotinib—CA2—neck—melanoma	0.000118	0.00434	CbGeAlD
Nilotinib—KIT—mammalian vulva—melanoma	0.000117	0.00433	CbGeAlD
Nilotinib—BRAF—lymph node—melanoma	0.000117	0.00432	CbGeAlD
Nilotinib—EPHB3—lymph node—melanoma	0.000116	0.00428	CbGeAlD
Nilotinib—TEK—head—melanoma	0.000116	0.00427	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—melanoma	0.000115	0.00422	CbGeAlD
Nilotinib—ABL1—skin of body—melanoma	0.000112	0.00413	CbGeAlD
Nilotinib—EPHB6—head—melanoma	0.000111	0.00408	CbGeAlD
Nilotinib—HCK—lymph node—melanoma	0.000107	0.00394	CbGeAlD
Nilotinib—ABL2—lymph node—melanoma	0.000106	0.00391	CbGeAlD
Nilotinib—PDGFRA—head—melanoma	0.000105	0.00387	CbGeAlD
Nilotinib—ABL1—mammalian vulva—melanoma	0.000102	0.00377	CbGeAlD
Nilotinib—EPHA4—lymph node—melanoma	9.7e-05	0.00358	CbGeAlD
Nilotinib—CA12—head—melanoma	9.69e-05	0.00357	CbGeAlD
Nilotinib—CA3—lymph node—melanoma	9.58e-05	0.00353	CbGeAlD
Nilotinib—MAP2K5—head—melanoma	9.47e-05	0.00349	CbGeAlD
Nilotinib—CSF1R—head—melanoma	9.24e-05	0.00341	CbGeAlD
Nilotinib—MAPK14—lymph node—melanoma	8.94e-05	0.0033	CbGeAlD
Nilotinib—FGR—lymph node—melanoma	8.91e-05	0.00328	CbGeAlD
Nilotinib—LCK—lymph node—melanoma	8.91e-05	0.00328	CbGeAlD
Nilotinib—CA2—eye—melanoma	8.76e-05	0.00323	CbGeAlD
Nilotinib—CA2—retina—melanoma	8.68e-05	0.0032	CbGeAlD
Nilotinib—EPHB4—lymph node—melanoma	8.48e-05	0.00313	CbGeAlD
Nilotinib—KIT—head—melanoma	8.39e-05	0.00309	CbGeAlD
Nilotinib—EPHA2—lymph node—melanoma	8.32e-05	0.00307	CbGeAlD
Nilotinib—PDGFRB—head—melanoma	8.2e-05	0.00302	CbGeAlD
Nilotinib—TEK—lymph node—melanoma	8.11e-05	0.00299	CbGeAlD
Nilotinib—EPHB6—lymph node—melanoma	7.75e-05	0.00286	CbGeAlD
Nilotinib—Ponatinib—ABCB1—melanoma	7.72e-05	0.0427	CrCbGaD
Nilotinib—CA1—head—melanoma	7.68e-05	0.00283	CbGeAlD
Nilotinib—CA2—skin of body—melanoma	7.62e-05	0.00281	CbGeAlD
Nilotinib—ABCB1—blood vessel—melanoma	7.52e-05	0.00277	CbGeAlD
Nilotinib—PDGFRA—lymph node—melanoma	7.35e-05	0.00271	CbGeAlD
Nilotinib—ABL1—head—melanoma	7.31e-05	0.00269	CbGeAlD
Nilotinib—CA2—mammalian vulva—melanoma	6.95e-05	0.00256	CbGeAlD
Nilotinib—MAP2K5—lymph node—melanoma	6.63e-05	0.00245	CbGeAlD
Nilotinib—CYP2B6—skin of body—melanoma	6.51e-05	0.0024	CbGeAlD
Nilotinib—CSF1R—lymph node—melanoma	6.47e-05	0.00239	CbGeAlD
Nilotinib—ABCG2—mammalian vulva—melanoma	6.44e-05	0.00237	CbGeAlD
Nilotinib—CA4—head—melanoma	6e-05	0.00221	CbGeAlD
Nilotinib—KIT—lymph node—melanoma	5.88e-05	0.00217	CbGeAlD
Nilotinib—PDGFRB—lymph node—melanoma	5.74e-05	0.00212	CbGeAlD
Nilotinib—Angiopathy—Temozolomide—melanoma	5.38e-05	0.00118	CcSEcCtD
Nilotinib—CA1—lymph node—melanoma	5.37e-05	0.00198	CbGeAlD
Nilotinib—Mental disorder—Carmustine—melanoma	5.37e-05	0.00118	CcSEcCtD
Nilotinib—Immune system disorder—Temozolomide—melanoma	5.35e-05	0.00117	CcSEcCtD
Nilotinib—Mediastinal disorder—Temozolomide—melanoma	5.34e-05	0.00117	CcSEcCtD
Nilotinib—Erythema—Carmustine—melanoma	5.34e-05	0.00117	CcSEcCtD
Nilotinib—Malnutrition—Carmustine—melanoma	5.34e-05	0.00117	CcSEcCtD
Nilotinib—Cough—Bleomycin—melanoma	5.34e-05	0.00117	CcSEcCtD
Nilotinib—Chills—Temozolomide—melanoma	5.32e-05	0.00116	CcSEcCtD
Nilotinib—Dehydration—Docetaxel—melanoma	5.3e-05	0.00116	CcSEcCtD
Nilotinib—Ill-defined disorder—Dactinomycin—melanoma	5.29e-05	0.00116	CcSEcCtD
Nilotinib—Anaemia—Dactinomycin—melanoma	5.27e-05	0.00115	CcSEcCtD
Nilotinib—Vomiting—Vemurafenib—melanoma	5.24e-05	0.00115	CcSEcCtD
Nilotinib—Alopecia—Temozolomide—melanoma	5.24e-05	0.00115	CcSEcCtD
Nilotinib—Dry skin—Docetaxel—melanoma	5.22e-05	0.00114	CcSEcCtD
Nilotinib—Myalgia—Bleomycin—melanoma	5.21e-05	0.00114	CcSEcCtD
Nilotinib—Chest pain—Bleomycin—melanoma	5.21e-05	0.00114	CcSEcCtD
Nilotinib—Abdominal pain upper—Docetaxel—melanoma	5.2e-05	0.00114	CcSEcCtD
Nilotinib—Rash—Vemurafenib—melanoma	5.2e-05	0.00114	CcSEcCtD
Nilotinib—Mental disorder—Temozolomide—melanoma	5.19e-05	0.00114	CcSEcCtD
Nilotinib—Dermatitis—Vemurafenib—melanoma	5.19e-05	0.00114	CcSEcCtD
Nilotinib—Back pain—Carmustine—melanoma	5.16e-05	0.00113	CcSEcCtD
Nilotinib—Headache—Vemurafenib—melanoma	5.16e-05	0.00113	CcSEcCtD
Nilotinib—Erythema—Temozolomide—melanoma	5.16e-05	0.00113	CcSEcCtD
Nilotinib—Malnutrition—Temozolomide—melanoma	5.16e-05	0.00113	CcSEcCtD
Nilotinib—Breast disorder—Docetaxel—melanoma	5.15e-05	0.00113	CcSEcCtD
Nilotinib—Discomfort—Bleomycin—melanoma	5.15e-05	0.00113	CcSEcCtD
Nilotinib—Malaise—Dactinomycin—melanoma	5.14e-05	0.00113	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Docetaxel—melanoma	5.13e-05	0.00112	CcSEcCtD
Nilotinib—ABL1—lymph node—melanoma	5.12e-05	0.00189	CbGeAlD
Nilotinib—Leukopenia—Dactinomycin—melanoma	5.11e-05	0.00112	CcSEcCtD
Nilotinib—Nasopharyngitis—Docetaxel—melanoma	5.1e-05	0.00111	CcSEcCtD
Nilotinib—Dysgeusia—Temozolomide—melanoma	5.05e-05	0.00111	CcSEcCtD
Nilotinib—Confusional state—Bleomycin—melanoma	5.03e-05	0.0011	CcSEcCtD
Nilotinib—Vision blurred—Carmustine—melanoma	5.03e-05	0.0011	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Docetaxel—melanoma	5.03e-05	0.0011	CcSEcCtD
Nilotinib—Tremor—Carmustine—melanoma	5e-05	0.00109	CcSEcCtD
Nilotinib—Oedema—Bleomycin—melanoma	4.99e-05	0.00109	CcSEcCtD
Nilotinib—Back pain—Temozolomide—melanoma	4.99e-05	0.00109	CcSEcCtD
Nilotinib—Imatinib—ALB—melanoma	4.98e-05	0.0275	CrCbGaD
Nilotinib—CA2—head—melanoma	4.97e-05	0.00183	CbGeAlD
Nilotinib—Infection—Bleomycin—melanoma	4.96e-05	0.00109	CcSEcCtD
Nilotinib—Anaemia—Carmustine—melanoma	4.94e-05	0.00108	CcSEcCtD
Nilotinib—Nausea—Vemurafenib—melanoma	4.89e-05	0.00107	CcSEcCtD
Nilotinib—Thrombocytopenia—Bleomycin—melanoma	4.89e-05	0.00107	CcSEcCtD
Nilotinib—Vision blurred—Temozolomide—melanoma	4.86e-05	0.00106	CcSEcCtD
Nilotinib—Myalgia—Dactinomycin—melanoma	4.86e-05	0.00106	CcSEcCtD
Nilotinib—Tremor—Temozolomide—melanoma	4.83e-05	0.00106	CcSEcCtD
Nilotinib—Discomfort—Dactinomycin—melanoma	4.8e-05	0.00105	CcSEcCtD
Nilotinib—Angina pectoris—Docetaxel—melanoma	4.8e-05	0.00105	CcSEcCtD
Nilotinib—Ill-defined disorder—Temozolomide—melanoma	4.79e-05	0.00105	CcSEcCtD
Nilotinib—Leukopenia—Carmustine—melanoma	4.78e-05	0.00105	CcSEcCtD
Nilotinib—Anaemia—Temozolomide—melanoma	4.77e-05	0.00104	CcSEcCtD
Nilotinib—Anorexia—Bleomycin—melanoma	4.76e-05	0.00104	CcSEcCtD
Nilotinib—Imatinib—ABCB1—melanoma	4.75e-05	0.0263	CrCbGaD
Nilotinib—Pancytopenia—Docetaxel—melanoma	4.68e-05	0.00102	CcSEcCtD
Nilotinib—Hypotension—Bleomycin—melanoma	4.66e-05	0.00102	CcSEcCtD
Nilotinib—Oedema—Dactinomycin—melanoma	4.66e-05	0.00102	CcSEcCtD
Nilotinib—Malaise—Temozolomide—melanoma	4.65e-05	0.00102	CcSEcCtD
Nilotinib—Vertigo—Temozolomide—melanoma	4.64e-05	0.00101	CcSEcCtD
Nilotinib—Infection—Dactinomycin—melanoma	4.63e-05	0.00101	CcSEcCtD
Nilotinib—Leukopenia—Temozolomide—melanoma	4.62e-05	0.00101	CcSEcCtD
Nilotinib—Hypertension—Carmustine—melanoma	4.61e-05	0.00101	CcSEcCtD
Nilotinib—Neutropenia—Docetaxel—melanoma	4.61e-05	0.00101	CcSEcCtD
Nilotinib—Palpitations—Temozolomide—melanoma	4.56e-05	0.000998	CcSEcCtD
Nilotinib—Thrombocytopenia—Dactinomycin—melanoma	4.56e-05	0.000997	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Bleomycin—melanoma	4.55e-05	0.000995	CcSEcCtD
Nilotinib—Chest pain—Carmustine—melanoma	4.55e-05	0.000995	CcSEcCtD
Nilotinib—Myalgia—Carmustine—melanoma	4.55e-05	0.000995	CcSEcCtD
Nilotinib—Anxiety—Carmustine—melanoma	4.53e-05	0.000991	CcSEcCtD
Nilotinib—Cough—Temozolomide—melanoma	4.5e-05	0.000985	CcSEcCtD
Nilotinib—Paraesthesia—Bleomycin—melanoma	4.48e-05	0.000981	CcSEcCtD
Nilotinib—Weight increased—Docetaxel—melanoma	4.48e-05	0.000981	CcSEcCtD
Nilotinib—Weight decreased—Docetaxel—melanoma	4.46e-05	0.000975	CcSEcCtD
Nilotinib—Hypertension—Temozolomide—melanoma	4.45e-05	0.000975	CcSEcCtD
Nilotinib—Dyspnoea—Bleomycin—melanoma	4.45e-05	0.000974	CcSEcCtD
Nilotinib—Anorexia—Dactinomycin—melanoma	4.44e-05	0.000971	CcSEcCtD
Nilotinib—Pneumonia—Docetaxel—melanoma	4.42e-05	0.000966	CcSEcCtD
Nilotinib—Confusional state—Carmustine—melanoma	4.39e-05	0.000961	CcSEcCtD
Nilotinib—Myalgia—Temozolomide—melanoma	4.39e-05	0.000961	CcSEcCtD
Nilotinib—Arthralgia—Temozolomide—melanoma	4.39e-05	0.000961	CcSEcCtD
Nilotinib—Infestation NOS—Docetaxel—melanoma	4.39e-05	0.000961	CcSEcCtD
Nilotinib—Infestation—Docetaxel—melanoma	4.39e-05	0.000961	CcSEcCtD
Nilotinib—Anxiety—Temozolomide—melanoma	4.38e-05	0.000958	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	4.36e-05	0.000955	CcSEcCtD
Nilotinib—Oedema—Carmustine—melanoma	4.36e-05	0.000953	CcSEcCtD
Nilotinib—Discomfort—Temozolomide—melanoma	4.34e-05	0.00095	CcSEcCtD
Nilotinib—Decreased appetite—Bleomycin—melanoma	4.34e-05	0.00095	CcSEcCtD
Nilotinib—Infection—Carmustine—melanoma	4.33e-05	0.000947	CcSEcCtD
Nilotinib—Acute coronary syndrome—Docetaxel—melanoma	4.33e-05	0.000947	CcSEcCtD
Nilotinib—Renal failure—Docetaxel—melanoma	4.32e-05	0.000944	CcSEcCtD
Nilotinib—Myocardial infarction—Docetaxel—melanoma	4.3e-05	0.000942	CcSEcCtD
Nilotinib—Neuropathy peripheral—Docetaxel—melanoma	4.3e-05	0.000942	CcSEcCtD
Nilotinib—Dry mouth—Temozolomide—melanoma	4.3e-05	0.00094	CcSEcCtD
Nilotinib—Jaundice—Docetaxel—melanoma	4.28e-05	0.000936	CcSEcCtD
Nilotinib—Stomatitis—Docetaxel—melanoma	4.28e-05	0.000936	CcSEcCtD
Nilotinib—Pain—Bleomycin—melanoma	4.27e-05	0.000934	CcSEcCtD
Nilotinib—Conjunctivitis—Docetaxel—melanoma	4.27e-05	0.000934	CcSEcCtD
Nilotinib—Thrombocytopenia—Carmustine—melanoma	4.27e-05	0.000934	CcSEcCtD
Nilotinib—Tachycardia—Carmustine—melanoma	4.25e-05	0.000931	CcSEcCtD
Nilotinib—CYP2B6—head—melanoma	4.25e-05	0.00157	CbGeAlD
Nilotinib—Confusional state—Temozolomide—melanoma	4.25e-05	0.000929	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dactinomycin—melanoma	4.24e-05	0.000928	CcSEcCtD
Nilotinib—Oedema—Temozolomide—melanoma	4.21e-05	0.000921	CcSEcCtD
Nilotinib—CA4—lymph node—melanoma	4.2e-05	0.00155	CbGeAlD
Nilotinib—Infection—Temozolomide—melanoma	4.18e-05	0.000915	CcSEcCtD
Nilotinib—Anorexia—Carmustine—melanoma	4.15e-05	0.000909	CcSEcCtD
Nilotinib—Hepatobiliary disease—Docetaxel—melanoma	4.15e-05	0.000909	CcSEcCtD
Nilotinib—Epistaxis—Docetaxel—melanoma	4.14e-05	0.000906	CcSEcCtD
Nilotinib—Nervous system disorder—Temozolomide—melanoma	4.13e-05	0.000904	CcSEcCtD
Nilotinib—Thrombocytopenia—Temozolomide—melanoma	4.12e-05	0.000902	CcSEcCtD
Nilotinib—Feeling abnormal—Bleomycin—melanoma	4.11e-05	0.0009	CcSEcCtD
Nilotinib—Skin disorder—Temozolomide—melanoma	4.09e-05	0.000895	CcSEcCtD
Nilotinib—Hypotension—Carmustine—melanoma	4.07e-05	0.000891	CcSEcCtD
Nilotinib—Hyperhidrosis—Temozolomide—melanoma	4.07e-05	0.000891	CcSEcCtD
Nilotinib—Decreased appetite—Dactinomycin—melanoma	4.05e-05	0.000886	CcSEcCtD
Nilotinib—Fatigue—Dactinomycin—melanoma	4.01e-05	0.000878	CcSEcCtD
Nilotinib—Anorexia—Temozolomide—melanoma	4.01e-05	0.000878	CcSEcCtD
Nilotinib—Pain—Dactinomycin—melanoma	3.98e-05	0.000871	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Carmustine—melanoma	3.97e-05	0.000869	CcSEcCtD
Nilotinib—Urticaria—Bleomycin—melanoma	3.97e-05	0.000868	CcSEcCtD
Nilotinib—ABCB1—retina—melanoma	3.97e-05	0.00146	CbGeAlD
Nilotinib—Haemoglobin—Docetaxel—melanoma	3.96e-05	0.000867	CcSEcCtD
Nilotinib—Rhinitis—Docetaxel—melanoma	3.95e-05	0.000865	CcSEcCtD
Nilotinib—Body temperature increased—Bleomycin—melanoma	3.95e-05	0.000863	CcSEcCtD
Nilotinib—Haemorrhage—Docetaxel—melanoma	3.94e-05	0.000862	CcSEcCtD
Nilotinib—Hepatitis—Docetaxel—melanoma	3.94e-05	0.000862	CcSEcCtD
Nilotinib—Insomnia—Carmustine—melanoma	3.94e-05	0.000862	CcSEcCtD
Nilotinib—Hypoaesthesia—Docetaxel—melanoma	3.92e-05	0.000858	CcSEcCtD
Nilotinib—Paraesthesia—Carmustine—melanoma	3.91e-05	0.000856	CcSEcCtD
Nilotinib—Pharyngitis—Docetaxel—melanoma	3.91e-05	0.000856	CcSEcCtD
Nilotinib—Urinary tract disorder—Docetaxel—melanoma	3.89e-05	0.000852	CcSEcCtD
Nilotinib—Dyspnoea—Carmustine—melanoma	3.89e-05	0.00085	CcSEcCtD
Nilotinib—Oedema peripheral—Docetaxel—melanoma	3.88e-05	0.00085	CcSEcCtD
Nilotinib—Connective tissue disorder—Docetaxel—melanoma	3.87e-05	0.000848	CcSEcCtD
Nilotinib—Urethral disorder—Docetaxel—melanoma	3.86e-05	0.000845	CcSEcCtD
Nilotinib—Feeling abnormal—Dactinomycin—melanoma	3.84e-05	0.000839	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Temozolomide—melanoma	3.84e-05	0.000839	CcSEcCtD
Nilotinib—Insomnia—Temozolomide—melanoma	3.81e-05	0.000833	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dactinomycin—melanoma	3.81e-05	0.000833	CcSEcCtD
Nilotinib—Visual impairment—Docetaxel—melanoma	3.8e-05	0.000831	CcSEcCtD
Nilotinib—Decreased appetite—Carmustine—melanoma	3.79e-05	0.000829	CcSEcCtD
Nilotinib—Paraesthesia—Temozolomide—melanoma	3.78e-05	0.000827	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Carmustine—melanoma	3.76e-05	0.000823	CcSEcCtD
Nilotinib—Dyspnoea—Temozolomide—melanoma	3.75e-05	0.000821	CcSEcCtD
Nilotinib—Erythema multiforme—Docetaxel—melanoma	3.73e-05	0.000815	CcSEcCtD
Nilotinib—Pain—Carmustine—melanoma	3.73e-05	0.000815	CcSEcCtD
Nilotinib—Constipation—Carmustine—melanoma	3.73e-05	0.000815	CcSEcCtD
Nilotinib—Dyspepsia—Temozolomide—melanoma	3.71e-05	0.000811	CcSEcCtD
Nilotinib—Eye disorder—Docetaxel—melanoma	3.68e-05	0.000806	CcSEcCtD
Nilotinib—Abdominal pain—Dactinomycin—melanoma	3.68e-05	0.000805	CcSEcCtD
Nilotinib—Body temperature increased—Dactinomycin—melanoma	3.68e-05	0.000805	CcSEcCtD
Nilotinib—Hypersensitivity—Bleomycin—melanoma	3.68e-05	0.000805	CcSEcCtD
Nilotinib—Decreased appetite—Temozolomide—melanoma	3.66e-05	0.000801	CcSEcCtD
Nilotinib—Flushing—Docetaxel—melanoma	3.66e-05	0.0008	CcSEcCtD
Nilotinib—Cardiac disorder—Docetaxel—melanoma	3.66e-05	0.0008	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Temozolomide—melanoma	3.64e-05	0.000795	CcSEcCtD
Nilotinib—Fatigue—Temozolomide—melanoma	3.63e-05	0.000794	CcSEcCtD
Nilotinib—Constipation—Temozolomide—melanoma	3.6e-05	0.000788	CcSEcCtD
Nilotinib—Pain—Temozolomide—melanoma	3.6e-05	0.000788	CcSEcCtD
Nilotinib—Feeling abnormal—Carmustine—melanoma	3.59e-05	0.000786	CcSEcCtD
Nilotinib—Asthenia—Bleomycin—melanoma	3.58e-05	0.000784	CcSEcCtD
Nilotinib—Angiopathy—Docetaxel—melanoma	3.58e-05	0.000782	CcSEcCtD
Nilotinib—Gastrointestinal pain—Carmustine—melanoma	3.56e-05	0.00078	CcSEcCtD
Nilotinib—Immune system disorder—Docetaxel—melanoma	3.56e-05	0.000779	CcSEcCtD
Nilotinib—Mediastinal disorder—Docetaxel—melanoma	3.55e-05	0.000777	CcSEcCtD
Nilotinib—Chills—Docetaxel—melanoma	3.54e-05	0.000774	CcSEcCtD
Nilotinib—Pruritus—Bleomycin—melanoma	3.53e-05	0.000773	CcSEcCtD
Nilotinib—Arrhythmia—Docetaxel—melanoma	3.52e-05	0.00077	CcSEcCtD
Nilotinib—Alopecia—Docetaxel—melanoma	3.48e-05	0.000762	CcSEcCtD
Nilotinib—CA2—lymph node—melanoma	3.48e-05	0.00128	CbGeAlD
Nilotinib—Feeling abnormal—Temozolomide—melanoma	3.47e-05	0.000759	CcSEcCtD
Nilotinib—Mental disorder—Docetaxel—melanoma	3.45e-05	0.000756	CcSEcCtD
Nilotinib—Body temperature increased—Carmustine—melanoma	3.44e-05	0.000754	CcSEcCtD
Nilotinib—Abdominal pain—Carmustine—melanoma	3.44e-05	0.000754	CcSEcCtD
Nilotinib—Gastrointestinal pain—Temozolomide—melanoma	3.44e-05	0.000753	CcSEcCtD
Nilotinib—Erythema—Docetaxel—melanoma	3.43e-05	0.000751	CcSEcCtD
Nilotinib—Malnutrition—Docetaxel—melanoma	3.43e-05	0.000751	CcSEcCtD
Nilotinib—Hypersensitivity—Dactinomycin—melanoma	3.43e-05	0.000751	CcSEcCtD
Nilotinib—Dysgeusia—Docetaxel—melanoma	3.36e-05	0.000735	CcSEcCtD
Nilotinib—Urticaria—Temozolomide—melanoma	3.35e-05	0.000732	CcSEcCtD
Nilotinib—Asthenia—Dactinomycin—melanoma	3.34e-05	0.000731	CcSEcCtD
Nilotinib—Body temperature increased—Temozolomide—melanoma	3.33e-05	0.000728	CcSEcCtD
Nilotinib—Abdominal pain—Temozolomide—melanoma	3.33e-05	0.000728	CcSEcCtD
Nilotinib—Back pain—Docetaxel—melanoma	3.32e-05	0.000726	CcSEcCtD
Nilotinib—Muscle spasms—Docetaxel—melanoma	3.3e-05	0.000722	CcSEcCtD
Nilotinib—ABCG2—lymph node—melanoma	3.23e-05	0.00119	CbGeAlD
Nilotinib—Hypersensitivity—Carmustine—melanoma	3.21e-05	0.000702	CcSEcCtD
Nilotinib—Diarrhoea—Dactinomycin—melanoma	3.19e-05	0.000697	CcSEcCtD
Nilotinib—ABCB1—mammalian vulva—melanoma	3.18e-05	0.00117	CbGeAlD
Nilotinib—Vomiting—Bleomycin—melanoma	3.17e-05	0.000694	CcSEcCtD
Nilotinib—Anaemia—Docetaxel—melanoma	3.17e-05	0.000694	CcSEcCtD
Nilotinib—CYP2D6—head—melanoma	3.16e-05	0.00116	CbGeAlD
Nilotinib—Rash—Bleomycin—melanoma	3.15e-05	0.000689	CcSEcCtD
Nilotinib—Dermatitis—Bleomycin—melanoma	3.14e-05	0.000688	CcSEcCtD
Nilotinib—Asthenia—Carmustine—melanoma	3.13e-05	0.000684	CcSEcCtD
Nilotinib—Hypersensitivity—Temozolomide—melanoma	3.1e-05	0.000679	CcSEcCtD
Nilotinib—Syncope—Docetaxel—melanoma	3.08e-05	0.000673	CcSEcCtD
Nilotinib—Leukopenia—Docetaxel—melanoma	3.07e-05	0.000672	CcSEcCtD
Nilotinib—Palpitations—Docetaxel—melanoma	3.03e-05	0.000663	CcSEcCtD
Nilotinib—Asthenia—Temozolomide—melanoma	3.02e-05	0.000661	CcSEcCtD
Nilotinib—Loss of consciousness—Docetaxel—melanoma	3.02e-05	0.00066	CcSEcCtD
Nilotinib—Cough—Docetaxel—melanoma	2.99e-05	0.000655	CcSEcCtD
Nilotinib—Diarrhoea—Carmustine—melanoma	2.98e-05	0.000652	CcSEcCtD
Nilotinib—Pruritus—Temozolomide—melanoma	2.98e-05	0.000652	CcSEcCtD
Nilotinib—Nausea—Bleomycin—melanoma	2.97e-05	0.000649	CcSEcCtD
Nilotinib—Hypertension—Docetaxel—melanoma	2.96e-05	0.000648	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—melanoma	2.96e-05	0.000648	CcSEcCtD
Nilotinib—Rash—Dactinomycin—melanoma	2.94e-05	0.000642	CcSEcCtD
Nilotinib—Chest pain—Docetaxel—melanoma	2.92e-05	0.000639	CcSEcCtD
Nilotinib—Arthralgia—Docetaxel—melanoma	2.92e-05	0.000639	CcSEcCtD
Nilotinib—Myalgia—Docetaxel—melanoma	2.92e-05	0.000639	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	2.9e-05	0.000635	CcSEcCtD
Nilotinib—Dizziness—Carmustine—melanoma	2.88e-05	0.00063	CcSEcCtD
Nilotinib—Diarrhoea—Temozolomide—melanoma	2.88e-05	0.00063	CcSEcCtD
Nilotinib—Dry mouth—Docetaxel—melanoma	2.86e-05	0.000625	CcSEcCtD
Nilotinib—Confusional state—Docetaxel—melanoma	2.82e-05	0.000618	CcSEcCtD
Nilotinib—Oedema—Docetaxel—melanoma	2.8e-05	0.000613	CcSEcCtD
Nilotinib—Dizziness—Temozolomide—melanoma	2.78e-05	0.000609	CcSEcCtD
Nilotinib—Infection—Docetaxel—melanoma	2.78e-05	0.000609	CcSEcCtD
Nilotinib—Vomiting—Carmustine—melanoma	2.77e-05	0.000606	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—melanoma	2.77e-05	0.000605	CcSEcCtD
Nilotinib—Shock—Docetaxel—melanoma	2.76e-05	0.000603	CcSEcCtD
Nilotinib—Rash—Carmustine—melanoma	2.75e-05	0.000601	CcSEcCtD
Nilotinib—Nervous system disorder—Docetaxel—melanoma	2.75e-05	0.000601	CcSEcCtD
Nilotinib—Dermatitis—Carmustine—melanoma	2.75e-05	0.000601	CcSEcCtD
Nilotinib—Thrombocytopenia—Docetaxel—melanoma	2.74e-05	0.0006	CcSEcCtD
Nilotinib—Tachycardia—Docetaxel—melanoma	2.73e-05	0.000598	CcSEcCtD
Nilotinib—Headache—Carmustine—melanoma	2.73e-05	0.000597	CcSEcCtD
Nilotinib—Skin disorder—Docetaxel—melanoma	2.72e-05	0.000595	CcSEcCtD
Nilotinib—Vomiting—Temozolomide—melanoma	2.68e-05	0.000586	CcSEcCtD
Nilotinib—Anorexia—Docetaxel—melanoma	2.67e-05	0.000584	CcSEcCtD
Nilotinib—Rash—Temozolomide—melanoma	2.66e-05	0.000581	CcSEcCtD
Nilotinib—Dermatitis—Temozolomide—melanoma	2.65e-05	0.00058	CcSEcCtD
Nilotinib—Headache—Temozolomide—melanoma	2.64e-05	0.000577	CcSEcCtD
Nilotinib—Hypotension—Docetaxel—melanoma	2.62e-05	0.000573	CcSEcCtD
Nilotinib—Nausea—Carmustine—melanoma	2.59e-05	0.000566	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Docetaxel—melanoma	2.55e-05	0.000558	CcSEcCtD
Nilotinib—Insomnia—Docetaxel—melanoma	2.53e-05	0.000554	CcSEcCtD
Nilotinib—Paraesthesia—Docetaxel—melanoma	2.51e-05	0.00055	CcSEcCtD
Nilotinib—Nausea—Temozolomide—melanoma	2.5e-05	0.000547	CcSEcCtD
Nilotinib—Dyspnoea—Docetaxel—melanoma	2.5e-05	0.000546	CcSEcCtD
Nilotinib—Dyspepsia—Docetaxel—melanoma	2.47e-05	0.000539	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—melanoma	2.43e-05	0.000533	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—melanoma	2.42e-05	0.000529	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—melanoma	2.41e-05	0.000528	CcSEcCtD
Nilotinib—Constipation—Docetaxel—melanoma	2.39e-05	0.000524	CcSEcCtD
Nilotinib—Pain—Docetaxel—melanoma	2.39e-05	0.000524	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—melanoma	2.31e-05	0.000505	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—melanoma	2.29e-05	0.000501	CcSEcCtD
Nilotinib—ABCB1—head—melanoma	2.27e-05	0.000838	CbGeAlD
Nilotinib—Abdominal pain—Docetaxel—melanoma	2.21e-05	0.000484	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—melanoma	2.21e-05	0.000484	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—melanoma	2.06e-05	0.000451	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—melanoma	2.01e-05	0.00044	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—melanoma	1.98e-05	0.000434	CcSEcCtD
Nilotinib—Diarrhoea—Docetaxel—melanoma	1.92e-05	0.000419	CcSEcCtD
Nilotinib—Dizziness—Docetaxel—melanoma	1.85e-05	0.000405	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—melanoma	1.78e-05	0.00039	CcSEcCtD
Nilotinib—Rash—Docetaxel—melanoma	1.77e-05	0.000386	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—melanoma	1.76e-05	0.000386	CcSEcCtD
Nilotinib—Headache—Docetaxel—melanoma	1.75e-05	0.000384	CcSEcCtD
Nilotinib—Nausea—Docetaxel—melanoma	1.66e-05	0.000364	CcSEcCtD
Nilotinib—ABCB1—lymph node—melanoma	1.59e-05	0.000587	CbGeAlD
Nilotinib—LYN—Signaling Pathways—CASP3—melanoma	2.61e-07	3.3e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—melanoma	2.6e-07	3.29e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—melanoma	2.59e-07	3.28e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—melanoma	2.59e-07	3.27e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—melanoma	2.58e-07	3.27e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CG—melanoma	2.58e-07	3.26e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—melanoma	2.57e-07	3.25e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—melanoma	2.57e-07	3.24e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—melanoma	2.56e-07	3.23e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF2—melanoma	2.55e-07	3.23e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—melanoma	2.55e-07	3.23e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—melanoma	2.54e-07	3.21e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—melanoma	2.53e-07	3.2e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—melanoma	2.53e-07	3.2e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—melanoma	2.53e-07	3.19e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—melanoma	2.53e-07	3.19e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—melanoma	2.52e-07	3.19e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—melanoma	2.52e-07	3.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—melanoma	2.52e-07	3.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—melanoma	2.52e-07	3.18e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—melanoma	2.51e-07	3.18e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—melanoma	2.51e-07	3.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—melanoma	2.51e-07	3.17e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK3—melanoma	2.51e-07	3.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—melanoma	2.5e-07	3.16e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—melanoma	2.5e-07	3.16e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—melanoma	2.49e-07	3.15e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—melanoma	2.49e-07	3.14e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—melanoma	2.48e-07	3.14e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—melanoma	2.48e-07	3.14e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—melanoma	2.48e-07	3.13e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—melanoma	2.48e-07	3.13e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—melanoma	2.48e-07	3.13e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—melanoma	2.48e-07	3.13e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—melanoma	2.47e-07	3.13e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—melanoma	2.47e-07	3.13e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—melanoma	2.47e-07	3.12e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—melanoma	2.46e-07	3.12e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—melanoma	2.46e-07	3.11e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—melanoma	2.46e-07	3.11e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—melanoma	2.46e-07	3.1e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—melanoma	2.45e-07	3.1e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—melanoma	2.45e-07	3.1e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—melanoma	2.44e-07	3.08e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—melanoma	2.44e-07	3.08e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—melanoma	2.43e-07	3.07e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PRKCA—melanoma	2.43e-07	3.07e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—melanoma	2.42e-07	3.06e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—melanoma	2.42e-07	3.05e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—melanoma	2.41e-07	3.04e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ERCC2—melanoma	2.41e-07	3.04e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—melanoma	2.39e-07	3.02e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—melanoma	2.39e-07	3.02e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—melanoma	2.39e-07	3.02e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—melanoma	2.39e-07	3.02e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—melanoma	2.38e-07	3.01e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—melanoma	2.38e-07	3.01e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—melanoma	2.37e-07	3e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—melanoma	2.37e-07	2.99e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—melanoma	2.36e-07	2.98e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—melanoma	2.36e-07	2.98e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—melanoma	2.35e-07	2.98e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—melanoma	2.34e-07	2.96e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP17A1—melanoma	2.34e-07	2.96e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—melanoma	2.34e-07	2.95e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—melanoma	2.33e-07	2.95e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—melanoma	2.33e-07	2.95e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—melanoma	2.33e-07	2.95e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—melanoma	2.33e-07	2.94e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—melanoma	2.33e-07	2.94e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—melanoma	2.32e-07	2.94e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—melanoma	2.32e-07	2.94e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—melanoma	2.31e-07	2.92e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—melanoma	2.31e-07	2.92e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—melanoma	2.3e-07	2.9e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.29e-07	2.89e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—melanoma	2.29e-07	2.89e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PRKCA—melanoma	2.29e-07	2.89e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—melanoma	2.27e-07	2.88e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ERCC2—melanoma	2.27e-07	2.87e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PRKCA—melanoma	2.27e-07	2.86e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—melanoma	2.26e-07	2.86e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—melanoma	2.26e-07	2.86e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—melanoma	2.26e-07	2.85e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—melanoma	2.26e-07	2.85e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—melanoma	2.25e-07	2.85e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ERCC2—melanoma	2.25e-07	2.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—melanoma	2.24e-07	2.84e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—melanoma	2.24e-07	2.83e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—melanoma	2.24e-07	2.83e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—melanoma	2.24e-07	2.83e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—melanoma	2.23e-07	2.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—melanoma	2.23e-07	2.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—melanoma	2.23e-07	2.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—melanoma	2.23e-07	2.82e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—melanoma	2.22e-07	2.81e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—melanoma	2.21e-07	2.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNA11—melanoma	2.21e-07	2.8e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—melanoma	2.2e-07	2.78e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—melanoma	2.2e-07	2.78e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—melanoma	2.19e-07	2.77e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—melanoma	2.19e-07	2.77e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—melanoma	2.19e-07	2.76e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—melanoma	2.18e-07	2.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—melanoma	2.18e-07	2.76e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—melanoma	2.18e-07	2.76e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—melanoma	2.17e-07	2.75e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FASN—melanoma	2.17e-07	2.74e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—melanoma	2.14e-07	2.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—melanoma	2.14e-07	2.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—melanoma	2.13e-07	2.7e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—melanoma	2.13e-07	2.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—melanoma	2.13e-07	2.69e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—melanoma	2.12e-07	2.69e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—melanoma	2.1e-07	2.66e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—melanoma	2.1e-07	2.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—melanoma	2.1e-07	2.65e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—melanoma	2.09e-07	2.65e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—melanoma	2.08e-07	2.63e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—melanoma	2.08e-07	2.63e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—melanoma	2.08e-07	2.63e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—melanoma	2.07e-07	2.62e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—melanoma	2.07e-07	2.62e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—melanoma	2.07e-07	2.62e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—melanoma	2.06e-07	2.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—melanoma	2.06e-07	2.6e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—melanoma	2.06e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GNAQ—melanoma	2.06e-07	2.6e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CD44—melanoma	2.06e-07	2.6e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—melanoma	2.04e-07	2.57e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—melanoma	2.03e-07	2.57e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—melanoma	2.03e-07	2.57e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—melanoma	2.03e-07	2.57e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—melanoma	2.03e-07	2.56e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—melanoma	2.02e-07	2.56e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—melanoma	2.02e-07	2.55e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—melanoma	2.01e-07	2.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—melanoma	2.01e-07	2.54e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—melanoma	2.01e-07	2.54e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—melanoma	2e-07	2.53e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—melanoma	2e-07	2.53e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—melanoma	1.99e-07	2.52e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—melanoma	1.99e-07	2.52e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—melanoma	1.98e-07	2.51e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—melanoma	1.97e-07	2.5e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1B1—melanoma	1.97e-07	2.49e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	1.96e-07	2.48e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—melanoma	1.96e-07	2.47e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—melanoma	1.94e-07	2.45e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—melanoma	1.93e-07	2.45e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—melanoma	1.93e-07	2.44e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—melanoma	1.92e-07	2.43e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—melanoma	1.92e-07	2.42e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—melanoma	1.92e-07	2.42e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—melanoma	1.9e-07	2.4e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—melanoma	1.9e-07	2.4e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—melanoma	1.89e-07	2.39e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—melanoma	1.89e-07	2.39e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—melanoma	1.89e-07	2.39e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—melanoma	1.88e-07	2.38e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—melanoma	1.88e-07	2.37e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—melanoma	1.87e-07	2.37e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.86e-07	2.35e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—melanoma	1.86e-07	2.35e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—melanoma	1.83e-07	2.32e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—melanoma	1.83e-07	2.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—melanoma	1.81e-07	2.29e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—melanoma	1.81e-07	2.29e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—melanoma	1.8e-07	2.27e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—melanoma	1.79e-07	2.27e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—melanoma	1.79e-07	2.26e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—melanoma	1.79e-07	2.26e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—melanoma	1.79e-07	2.26e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—melanoma	1.78e-07	2.25e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—melanoma	1.77e-07	2.24e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	1.77e-07	2.23e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—melanoma	1.74e-07	2.19e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—melanoma	1.73e-07	2.19e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—melanoma	1.73e-07	2.18e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—melanoma	1.72e-07	2.17e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—melanoma	1.71e-07	2.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—melanoma	1.71e-07	2.16e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—melanoma	1.71e-07	2.16e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—melanoma	1.69e-07	2.14e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—melanoma	1.67e-07	2.11e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—melanoma	1.67e-07	2.11e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—melanoma	1.67e-07	2.11e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—melanoma	1.67e-07	2.11e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—melanoma	1.66e-07	2.09e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—melanoma	1.65e-07	2.09e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—melanoma	1.65e-07	2.08e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—melanoma	1.64e-07	2.08e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—melanoma	1.64e-07	2.07e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—melanoma	1.63e-07	2.06e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—melanoma	1.63e-07	2.06e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—melanoma	1.63e-07	2.06e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—melanoma	1.62e-07	2.05e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—melanoma	1.6e-07	2.02e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—melanoma	1.6e-07	2.02e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—melanoma	1.59e-07	2e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—melanoma	1.58e-07	2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—melanoma	1.57e-07	1.99e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—melanoma	1.56e-07	1.98e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—melanoma	1.56e-07	1.97e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—melanoma	1.55e-07	1.96e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—melanoma	1.54e-07	1.95e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—melanoma	1.54e-07	1.95e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—melanoma	1.53e-07	1.93e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—melanoma	1.52e-07	1.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PRKCA—melanoma	1.49e-07	1.89e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ERCC2—melanoma	1.48e-07	1.87e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—melanoma	1.46e-07	1.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—melanoma	1.45e-07	1.83e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—melanoma	1.44e-07	1.83e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—melanoma	1.44e-07	1.82e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—melanoma	1.44e-07	1.82e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—melanoma	1.42e-07	1.79e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—melanoma	1.41e-07	1.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—melanoma	1.37e-07	1.73e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—melanoma	1.37e-07	1.73e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—melanoma	1.36e-07	1.72e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—melanoma	1.36e-07	1.72e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—melanoma	1.35e-07	1.7e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—melanoma	1.34e-07	1.7e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—melanoma	1.34e-07	1.69e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—melanoma	1.31e-07	1.66e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—melanoma	1.26e-07	1.59e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—melanoma	1.25e-07	1.59e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—melanoma	1.2e-07	1.52e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—melanoma	1.19e-07	1.5e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—melanoma	1.18e-07	1.49e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—melanoma	1.17e-07	1.48e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—melanoma	1.16e-07	1.46e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—melanoma	1.13e-07	1.43e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—melanoma	1.03e-07	1.3e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—melanoma	1.02e-07	1.29e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—melanoma	1.02e-07	1.28e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—melanoma	9.83e-08	1.24e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—melanoma	8.97e-08	1.13e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—melanoma	8.89e-08	1.12e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—melanoma	8.87e-08	1.12e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—melanoma	8.36e-08	1.06e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—melanoma	8.32e-08	1.05e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—melanoma	8.29e-08	1.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—melanoma	7.75e-08	9.8e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—melanoma	7.25e-08	9.16e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—melanoma	6.83e-08	8.64e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—melanoma	6.77e-08	8.56e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—melanoma	5.47e-08	6.91e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—melanoma	4.47e-08	5.65e-07	CbGpPWpGaD
